Volpara Health Technologies Ltd. announced to attend this year's National Consortium of Breast Centers (NCoBC) conference in Las Vegas to showcase its software advancements that are powering today's progressive breast centers. The US Food and Drug Administration (FDA) recently announced a federal regulation requiring all women to be notified--with standard language--of their breast density in mammography results letters. NCoBC marks the industry's first conference since the announced regulation and Volpara will demonstrate its market leading software to assist providers in better serving women with dense breasts: Volpara Scorecard™?

is the number one artificial intelligence software for automated, volumetric breast density assessment. Research has shown that radiologists who assess breast density visually assign density categories consistently.1 With the new federal language of dense vs. non-dense, distinguishing a patient's breast density between a BI-RADS®?

category b and c accurately and consistently will be essential. Volpara Scorecard's objective TruDensity®? algorithm is proven to reduce reader variability.

Volpara Thumbnail™? goes the extra mile to help patients understand their own breast density with image-enhanced results letters. The innovative letter section shows both images of a patient's own breast tissue, as well as sample images indicating the difference in breast density categories and its impact on their care options.

These simple-to-understand explanations and visuals aim to increase patient engagement and are paired with access to an educational website offering a deeper dive into these topics. Volpara also offers Professional Services to help customers educate referrers and patients and to maximize the value of dense breast screening programs. Volpara also offers Professional Services to help customers educate referrers and patients and to maximize the value of dense breast screening programs. Assess patient risk beyond breast cancer Volpara Risk Pathways™ provides a smooth workflow for healthcare providers assessing hereditary and lifetime breast cancer risk. Volpara interfaces with major genetics labs—including Ambry, Myriad, Natera, and Invitae—to improve the test request process and results delivery.

The Risk Pathways lab connections offer the freedom to select a preferred lab or work with multiple labs as needs and/or patient insurance coverage requirements change. Risk Pathways also allows providers to look beyond breast cancer risk and identify the patient risk of colorectal, ovarian, endometrial, and pancreatic cancer. This enables greater partnership between the breast center and oncology departments, primary care providers, and OB/GYNs for true population health impact.

Survey patients from home Healthcare providers nationwide are facing staffing and workload challenges. Centers using Volpara's mammography reporting system, Patient Hub™ now have a new pre-appointment patient survey to reduce patient stress and improve data collection. The survey pairs patient intake and cancer risk assessment questions in one survey to complete from the comfort of home.

Patients can conveniently collect information in a relaxed setting without the time pressures of the waiting room. Instead of collecting patient data, front desk staff, patient navigators, and technologists can spend valuable appointment time better understanding the information provided.